Clinical Trials · NCT01140893
Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
- Phase
- Phase 2/Phase 3
- Recruitment status
- Unknown
- Sponsor
- University Hospital, Caen
- Enrollment
- 110
- Start date
- Nov 2010
- Locations
- 3 sites, France
- Primary endpoint
- Change from baseline to 6 months of centrally measured HbA1c